News briefing: Chinese cancer player gets $124M+ Series C; IN8bio sets terms for $86M IPO
A little less than two years after a nine-figure Series B, Apollomics has returned to the venture well.
This time, the company has come out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
